Home›Cardiology› Gut microbiota metabolites drive or protect against atherosclerosis via immune signaling pathways
Gut microbiota metabolites drive or protect against atherosclerosis via immune signaling pathwaysGut Bacteria Influence the Progression of Heart Disease
Frontiers in MedicinePublished July 18, 2026Study authors: Yongang Li, Jinheng Zhu, Mingkui Huang, Xuan Liu, Liezhi WangDOI ↗Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Consider the gut microbiota–immune axis as an emerging, not yet established, target in atherosclerosis.
This systematic review examines the role of gut microbiota and microbial-derived signaling molecules in atherosclerosis pathogenesis. The authors synthesize evidence that pro-atherogenic molecules—lipopolysaccharides, outer membrane vesicles, extracellular nucleic acids, and TMAO—activate Toll-like receptors, the NLRP3 inflammasome, and nucleic acid–sensing pathways, promoting inflammatory cytokine production, endothelial dysfunction, and foam cell formation. Conversely, beneficial microbial metabolites such as short-chain fatty acids, bile acids, and tryptophan-derived metabolites exert immunomodulatory and vasculoprotective effects via FFAR2/3, AhR, FXR, and TGR5 signaling.
The review highlights the microbiota–innate immune axis as a potential target for future disease prevention, risk stratification, and precision therapeutics. However, the authors describe these strategies as "emerging" and not established clinical treatments. Limitations are not reported in the review, and no pooled effect sizes are provided. The evidence is largely mechanistic, linking microbial products to inflammatory pathways.
Practice relevance is restrained: while the axis offers a promising framework, therapeutic applications remain preclinical. Clinicians should interpret these findings as hypothesis-generating rather than actionable. Further research is needed to translate these mechanisms into validated interventions.
How this fits prior evidence
This systematic review extends prior coverage of gut microbiota modulation by natural products (polyphenols, berberine) by detailing specific microbial signaling pathways and metabolites involved in atherosclerosis. It complements findings on mechanopriming and ferroptosis by adding an immune-microbial dimension to endothelial dysfunction and plaque progression. The review does not address clinical outcomes, contrasting with the mortality data from pre-transplant coronary artery disease studies.
This review looked at how the gut microbiome affects atherosclerosis, a condition where plaque builds up in the arteries. Researchers found that certain substances produced by microbes, such as lipopolysaccharides and TMAO, can trigger inflammation. These specific molecules are linked to problems like damaged blood vessel linings and the formation of foam cells, which contribute to heart disease.
On the other hand, the study identified beneficial microbial metabolites like short-chain fatty acids and bile acids. These substances may have protective effects on the blood vessels and help regulate the immune system. They work through specific signaling pathways that can help manage inflammation.
Because this is a systematic review of emerging science, these findings are not yet used as standard medical treatments. The research suggests that the link between gut health and heart disease could lead to new ways to prevent illness or tailor treatments in the future. Patients should speak with a doctor about how gut health relates to their specific heart health needs.
What this means for you:
Gut microbes produce both harmful and helpful substances that influence heart health and artery inflammation.
Common questions
How do gut bacteria affect heart health?
The gut microbiome interacts with the immune system to influence atherosclerosis. Some microbial products, like lipopolysaccharides and TMAO, can trigger inflammation and damage blood vessels. Other substances, such as short-chain fatty acids and bile acids, may have protective effects on the cardiovascular system.
What are the harmful components found in the gut?
Certain microbial-derived signaling molecules can be harmful. These include lipopolysaccharides, outer membrane vesicles, extracellular nucleic acids, and TMAO. These specific substances can activate inflammatory pathways that lead to endothelial dysfunction and the formation of foam cells in the arteries.
Are these findings used for treatment today?
No, these are not currently established clinical treatments. The research identifies the gut-immune axis as a potential target for future prevention and precision therapies. You should consult a healthcare professional regarding any changes to your current medical management.
Atherosclerosis (AS) is a complex cardiovascular disease driven by the interplay of dysregulated lipid metabolism, chronic inflammation, and immune dysfunction. Increasing evidence has revealed that the gut microbiota not only regulates host metabolic homeostasis but also actively contributes to the initiation and progression of AS through intricate interactions with the innate immune system. Microbial-derived signaling molecules, including lipopolysaccharides, outer membrane vesicles, extracellular nucleic acids, and TMAO, can activate Toll-like receptors, the NLRP3 inflammasome, and nucleic acid–sensing pathways, thereby promoting inflammatory cytokine production, endothelial dysfunction, and foam cell formation. In contrast, beneficial microbial metabolites such as short-chain fatty acids, bile acids, and tryptophan-derived metabolites exert immunomodulatory and vasculoprotective effects through signaling pathways involving FFAR2/3, the AhR, the FXR, and TGR5. Conversely, the innate immune system shapes microbial composition and function through barrier defense, phagocytic clearance, and antimicrobial factor production, establishing a dynamic and reciprocal microbiota–immune interaction network. This review systematically summarizes alterations in microbial ecology and innate immune homeostasis associated with atherosclerosis, elucidates the key molecular mechanisms underlying microbiota–innate immune crosstalk, and examines its dynamic involvement across four critical stages of disease evolution: endothelial dysfunction, foam cell formation, plaque progression, and plaque destabilization and rupture. In addition, emerging therapeutic approaches, including microbiota remodeling, modulation of microbial metabolic pathways, and precision microbiome-based interventions, are comprehensively discussed. The microbiota–innate immune axis provides a novel conceptual framework for understanding atherosclerosis pathogenesis and represents a promising target for future disease prevention, risk stratification, and precision therapeutics.
